Abstract:BP is the most important determinant of the risk of stroke. A small reduction in BP results in a substantial reduction of both ischemic and hemorrhagic stroke. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental evidence has linked the renin-angiotensin system (RAS) to the development and progression of cerebrovascular disease. Inhibition of the RAS has beneficial cerebrovascular effects and may reduce the risk of stroke in a manner possibly independent from the alterations of BP. Some clinical trials even suggest that ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) exert cerebroprotective effects beyond BP lowering, but the evidence is controversial. Studies on specific protective actions of antihypertensive drugs are generally hampered by the fact that any treatment-related difference in BP may play a dominant role in the prevention of stroke. There are also indications that the protective potency of ARBs might be superior to that of ACE inhibitors, due to their differential activation of angiotensin II type 2 receptors, but the clinical relevance of this mechanism is unclear. Some studies in primary prevention of stroke, acute stroke, and secondary prevention show advantages for ARBs beyond controlling BP alone. In primary prevention, the LIFE randomized trial showed a significant difference in stroke rate in favor of losartan compared with atenolol despite similar reductions in BP. In acute stroke, the role of hypertension and its treatment remains controversial. ACCESS, however, suggested that an ARB is safe in hypertensive acute stroke patients and may offer advantages independent from BP control. In secondary stroke prevention, there are very few antihypertensive trials. These trials show that BP lowering is at least as successful as in primary prevention, but the absolute stroke risk is much higher. An ACE inhibitor was effective compared with placebo in the PROGRESS trial. The MOSES study showed that eprosartan prevented vascular events more effectively than nitrendipine, despite similar BP-lowering effects. Hypertension is not only the most important risk factor for stroke, but is also closely correlated with cognitive decline and dementia. Therefore, prevention of cognitive decline or even improvement of slightly diminished brain function should be an important goal for antihypertensive treatment in the future. Some clinical data suggest advantages for ACE inhibitors, ARBs, and calcium channel antagonists. Currently, however, the existing data are not sufficient for clinical recommendations. Therefore, ongoing trials will further define the exact role of inhibitors of the RAS and are urgently needed in secondary prevention, in acute stroke, and in the prevention of cognitive decline.

Amlodipine and Stroke Prevention.

New Medicine for Antithrombotic Treatment of Atrial Fibrillation—Who Can Dominate in the Future

Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: a Quantitative Overview.

Primary and Secondary Prevention of Stroke by Antihypertensive Drug Treatment.

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Angiotensin-converting Enzyme Inhibitor for Prevention of Stroke

Antihypertensive Treatment and Prevention of Stroke and Dementia

Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta-Analysis in 20,451 Hypertensive Patients.

Role Of Blood Pressure Management In Stroke Prevention: A Systematic Review And Network Meta-Analysis Of 93 Randomized Controlled Trials

PCV15 A Cost-Effectiveness Analysis Between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China

Incident stroke events in clinical trials of antihypertensive drugs in cardiovascular disease patients: A network meta-analysis of randomized controlled trials

Inhibition of the renin-angiotensin system and the prevention of stroke

Blood Pressure Reduction and Cardiovascular Prevention: an Update Including the 2003–2004 Secondary Prevention Trials

Comparative Effects Of Antihypertensive Drugs On Stroke Outcome In China

Angiotensin At1-Receptor Blockers And Cerebrovascular Protection: Do They Actually Have A Cutting Edge Over Angiotensin-Converting Enzyme Inhibitors?

Stroke Prevention in Atrial Fibrillation--an Asian Stroke Perspective.

Conventional Therapy and Newer Drug Classes for Cardiovascular Protection in Hypertension.

Unlocking the Medicinal Mysteries: Preventing Lacunar Stroke with Drug Repurposing

Clinical Evidence of Ca2+ Channel Blocker in Stroke Prevention

Antihypertensive Therapies with Acute Stroke

Does A Change In Angiotensin Ii Formation Caused By Antihypertensive Drugs Affect The Risk Of Stroke? A Meta-Analysis Of Trials According To Treatment With Potentially Different Effects On Angiotensin Ii